OPEN

DATA REPORT

Polymorphisms in the *TMEM132D* region are associated with panic disorder in *HLA-DRB1*13:02*-negative individuals of a Japanese population

Mihoko Shimada-Sugimoto[1], Takeshi Otowa[2], Taku Miyagawa[1,3], Seik-Soon Khor[1], Yosuke Omae[1], Licht Toyo-oka[1], Nagisa Sugaya[4], Yoshiya Kawamura[5], Tadashi Umekage[6], Akinori Miyashita[7], Ryozo Kuwano[7], Hisanobu Kaiya[8], Kiyoto Kasai[9], Hisashi Tanii[10], Yuji Okazaki[11], Katsushi Tokunaga[1] and Tsukasa Sasaki[12]

We herein report an association between *TMEM132D* and panic disorder (PD) in a Japanese population, evaluating the effects of *HLA-DRB1*13:02*, which we previously reported as a susceptibility genetic factor for PD. SNPs in *TMEM132D* showed significant associations with PD in subjects without *HLA-DRB1*13:02* (rs4759997; $P = 5.02 \times 10^{-6}$, odds ratio = 1.50) but not in those with the *HLA* allele. *TMEM132D* might have a role in the development of PD in subjects without *HLA-DRB1*13:02*.

Human Genome Variation (2016) **3**, 16001; doi:10.1038/hgv.2016.1; published online 25 February 2016

Panic disorder (PD) is an anxiety disorder characterized by panic attacks and anticipatory anxiety. PD is relatively common; the lifetime prevalence is reported to be 1–3%.[1] According to a previous twin study, the heritability of PD is estimated to be 0.43,[2] which suggests that both genetic and environmental factors have a role in the pathogenesis of PD. To date, several studies that applied a candidate-gene approach have reported susceptibility genes of PD, but many of them have not been successfully replicated in subsequent studies.[3] Recently, a genome-wide association study (GWAS) of European ancestry identified single-nucleotide polymorphisms (SNPs) in the transmembrane protein 132D gene (*TMEM132D*) associated with PD.[4] This result was supported by a replication study and meta-analyses of European subjects, which confirmed that *TMEM132D* is a susceptibility gene of PD.[5,6] However, in a Japanese GWAS of PD, SNPs in *TMEM132D* did not show a positive association with PD.[7,8]

We previously found associations between PD and human leukocyte antigen (HLA), especially the *HLA-B* and *HLA-DRB1* genes, based on pathway analyses using the results from our Japanese GWAS of PD.[8] HLA is the human version of the major histocompatibility complex, which presents endogenous antigens to CD8+ and CD4+ T cells. There is a great number of polymorphisms in the *HLA* genes. *HLA* genes have been reported to be involved in not only immune-related diseases[9] but also several psychiatric disorders.[10] We genotyped the *HLA-B* and *HLA-DRB1* genes, and confirmed that the frequency of *HLA-DRB1*13:02* was significantly higher in PD patients than in healthy individuals (case positivity: 18.1%; control positivity: 11.5%; $P = 2.62 \times 10^{-5}$; odds ratio (OR) = 1.70).[11]

Previous studies have reported that the genetic factors and clinical features of several *HLA*-associated diseases differ between *HLA* allele-positive and -negative patients. Narcolepsy, with and without cataplexy, was associated with *HLA-DQB1*06:02*,[12] and the severity of narcolepsy without cataplexy was higher in *HLA-DQB1*06:02*-positive patients than in *HLA-DQB1*06:02*-negative patients.[12,13] *HLA-B*51* was strongly associated with risk factors for Behçet's disease,[14] and a significant association between one SNP in the *ERAP1* locus was observed only in *HLA-B*51*-positive patients.[14] Hence there is a possibility that the genetic backgrounds might differ in PD subjects with or without *HLA-DRB1*13:02*. To account for these effects of *HLA* alleles, we focused on a candidate PD gene, *TMEM132D*, and investigated the SNPs in the *TMEM132D* region in both *HLA-DRB1*13:02*-positive and -negative subjects. In this analysis, genotyping data for the SNPs were generated using the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). Inclusion criteria for quality control were SNP call rate > 0.95, Hardy–Weinberg equilibrium (HWE) test $P > 0.001$, and minor allele frequency (MAF) > 0.05. We defined 'gene region' as the region located 50 kb upstream to 50 kb downstream of *TMEM132D* (chr12: 129556271–130388212 (GRCh37/hg19)). The SNP genotype data were subdivided into two data sets, those of *HLA-DRB1*13:02*-positive subjects (cases: $N = 103$; controls: $N = 198$) and those of *HLA-DRB1*13:02*-negative subjects (cases: $N = 438$; controls: $N = 1,341$). An imputation analysis was also performed to evaluate the potential association of ungenotyped SNPs in the *TMEM132D* region of both subgroups. IMPUTE2 software[15] was used to estimate SNP genotypes using the reference data set from 1000 Genomes Phase 3 haplotypes.[15] We filtered out low-quality imputed SNPs by applying the

[1]Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; [2]Graduate School of Clinical Psychology, Teikyo Heisei University Major of Professional Clinical Psychology, Tokyo, Japan; [3]Department of Psychiatry and Behavioral Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan; [4]Department of Epidemiology and Public Health, Graduate School of Medicine, Yokohama City University, Kanagawa, Japan; [5]Department of Psychiatry, Shonan Kamakura General Hospital, Kanagawa, Japan; [6]Division for Environment, Health and Safety, The University of Tokyo, Tokyo, Japan; [7]Department of Molecular Genetics, Center for Bioresources, Brain Research Institute, Niigata University, Niigata, Japan; [8]Panic Disorder Research Center, Warakukai Med. Corp., Tokyo, Japan; [9]Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; [10]Department of Psychiatry, Institute of Medical Life Science, Graduate School of Medicine, Mie University, Mie, Japan; [11]Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan and [12]Department of Physical and Health Education, Graduate School of Education, The University of Tokyo, Tokyo, Japan.
Correspondence: T Otowa (totowa-psy@umin.org)
Received 19 October 2015; revised 8 December 2015; accepted 9 December 2015

following conditions: SNP call rate $\geqslant 0.95$, HWE test $P > 0.0001$, and probability of imputation certainty $\geqslant 0.9$. After filtering, a total of 8,070 SNPs remained for subsequent analysis. Using the genotype data of these SNPs, case–control association tests were performed to examine whether SNPs in *TMEM132D* showed an association with PD in each subgroup. We set the significance level after multiple testing correction to $\alpha = 1.26 \times 10^{-5}$, which was calculated from 0.05 divided by the number of SNPs ($N = 3,978$) pruned

by high linkage disequilibrium (LD; $r^2 > 0.8$) with PLINK SNP pruning procedure (window size in SNPs = 100, the number of SNPs to shift the window = 1).[16]

In the analysis of the *HLA-DRB1*13:02*-negative subgroup, nine SNPs in the *TMEM132D* region showed significant associations, and SNP rs4759997 had the lowest P value ($P = 5.02 \times 10^{-6}$, OR = 1.50; Table 1 and Figure 1). In contrast, these SNPs were found to have no association with PD in the *HLA-DRB1*13:02*-

Table 1. SNPs with P-value $< 10^{-4}$ in the *TMEM132D* region

Position[a]	SNP	HLA-DRB1*13:02 negative				HLA-DRB1*13:02 positive			
		MAF		P-value	OR	MAF		P-value	OR
		PD	Control			PD	Control		
130185851	rs1567509	0.283	0.210	1.01×10^{-5b}	1.49	0.211	0.203	0.820	1.05
130186374	rs7311162	0.279	0.205	5.87×10^{-6b}	1.50	0.199	0.198	0.975	1.01
130187014	rs264463	0.105	0.064	4.79×10^{-5}	1.73	0.050	0.054	0.854	0.93
130187283	rs1397504	0.281	0.208	6.92×10^{-6b}	1.49	0.199	0.200	0.989	1.00
130187566	rs264464	0.104	0.063	5.30×10^{-5}	1.73	0.050	0.054	0.854	0.93
130188352	rs264465	0.105	0.063	4.19×10^{-5}	1.73	0.058	0.061	0.908	0.96
130188504	rs7962650	0.279	0.206	7.32×10^{-6b}	1.49	0.194	0.200	0.876	0.97
130189452	rs67208922	0.104	0.063	5.46×10^{-5}	1.72	0.050	0.054	0.833	0.92
130189478	rs264468	0.104	0.063	5.46×10^{-5}	1.72	0.050	0.054	0.833	0.92
130189868	rs10773696	0.279	0.206	8.65×10^{-6b}	1.49	0.194	0.200	0.876	0.97
130190130	rs7312812	0.279	0.207	1.19×10^{-5b}	1.48	0.194	0.199	0.888	0.97
130190285	rs1510820	0.279	0.207	9.10×10^{-6b}	1.48	0.194	0.200	0.876	0.97
130191111	rs7132791	0.279	0.207	9.10×10^{-6b}	1.48	0.194	0.200	0.876	0.97
130191332	rs264472	0.104	0.063	5.90×10^{-5}	1.72	0.050	0.056	0.745	0.88
130191567	rs2398467	0.104	0.063	5.90×10^{-5}	1.72	0.049	0.056	0.725	0.87
130191851	rs529395389	0.104	0.063	6.92×10^{-5}	1.71	0.049	0.056	0.716	0.87
130192489	rs588761	0.104	0.063	5.90×10^{-5}	1.72	0.049	0.056	0.716	0.87
130193038	rs4759997	0.282	0.208	5.02×10^{-6b}	1.50	0.199	0.200	0.989	1.00
130193940	rs663071	0.104	0.064	9.67×10^{-5}	1.69	0.049	0.056	0.716	0.87
130195133	rs67408383	0.104	0.063	6.03×10^{-5}	1.72	0.049	0.056	0.716	0.87
130195225	rs7304093	0.279	0.208	1.31×10^{-5}	1.47	0.194	0.200	0.876	0.97
130199905	rs6486497	0.356	0.286	8.73×10^{-5}	1.38	0.257	0.293	0.356	0.84
130201128	rs10744430	0.366	0.292	3.19×10^{-5}	1.41	0.277	0.296	0.630	0.91
130210550	rs76801035	0.055	0.027	9.36×10^{-5}	2.07	0.025	0.020	0.738	1.21

Abbreviations: MAF, minor allele frequency; OR, odds ratio; PD, panic disorder; SNP, single-nucleotide polymorphism. [a]Physical position (according to GRCh37/hg19). [b]The significance level after multiple testing correction was set as $\alpha = 1.26 \times 10^{-5}$.


Figure 1. Results of the *HLA-DRB1*13:02*-negative subgroup analysis in the *TMEM132D* region. Physical positions are based on GRCh37/hg19. The blue line represents the significance threshold ($\alpha = 1.26 \times 10^{-5}$).

positive group (Table 1 and Supplementary Figure 1). To find other SNPs potentially associated with PD in the *HLA-DRB1*13:02*-negative group, logistic regression analysis adjusting for the effect of rs4759997 was also performed. The analysis showed that none of the SNPs in the *TMEM132D* region had an association that reached the threshold level of significance, which suggested that the nominal associations of SNPs in this region were derived from LD with rs4759997 (Supplementary Figure 2).

A previous study identified two SNPs, rs7309727 and rs11060369, in *TMEM132D* as susceptibility variants for PD in populations of European ancestry.[4] The two SNPs were also associated with higher anxiety and larger amygdala volumes.[17] In addition, the risk genotype of rs11060369 was found to enhance *TMEM132D* mRNA expression in the brain.[4] These two SNPs identified in populations of European ancestry were located in intron 3 of *TMEM132D*, while the SNPs found in our study, rs4759997 and the surrounding SNPs with significant *P* values, were located in intron 1. The SNP with the lowest *P* value, rs4759997, was not in LD with either rs7309727 or rs11060369 in individuals of Japanese ancestry (Japanese; rs7309727, $r^2 = 0.001$; rs11060369, $r^2 = 0.003$), while in individuals of European ancestry, SNP rs4759997 had very low frequency (MAF = 0.009) according to HapMap data.[18,19] In addition, imputation analysis revealed that the two SNPs, rs7309727 and rs11060369, were not associated with PD in *HLA-DRB1*13:02*-negative Japanese subjects (rs7309727: case MAF = 0.36, control MAF = 0.39, *P* = 0.124; rs11060369: case MAF = 0.46, control MAF = 0.46, *P* = 0.826). Such results, showing that different SNPs in *TMEM132D* are associated with PD in individual populations, might be derived from differences in the LD structure between the populations of Japanese and European ancestry (Supplementary Figure 3). Therefore, targeted resequencing of this gene is required in a future study.

Our study provides initial evidence that SNPs in *TMEM132D* show significant associations with PD in a *HLA-DRB1*13:02*-negative group of Japanese individuals. Specifically, *TMEM132D* might affect PD in *HLA-DRB1*13:02*-negative individuals. Further replication studies in independent and larger *HLA*-typed population samples are required to confirm these associations.

HGV DATABASE

The relevant data from this Data Report are hosted at the Human Genome Variation Database at http://dx.doi.org/10.6084/m9.figshare.hgv.771.

COMPETING INTERESTS

The authors declare no conflict of interest.

REFERENCES

1 Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. *Am J Psychiatry* 1994; **151**: 413–420.

2 Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. *Am J Psychiatry* 2001; **158**: 1568–1578.

3 Na HR, Kang EH, Lee JH, Yu BH. The genetic basis of panic disorder. *J Korean Med Sci* 2011; **26**: 701–710.

4 Erhardt A, Czibere L, Roeske D, Lucae S, Unschuld PG, Ripke S *et al*. TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. *Mol Psychiatry* 2011; **16**: 647–663.

5 Erhardt A, Akula N, Schumacher J, Czamara D, Karbalai N, Müller-Myhsok B *et al*. Replication and meta-analysis of TMEM132D gene variants in panic disorder. *Transl Psychiatry* 2012; **2**: e156.

6 Howe AS, Buttenschøn HN, Bani-Fatemi A, Maron E, Otowa T, Erhardt A *et al*. Candidate genes in panic disorder: meta-analyses of 23 common variants in major anxiogenic pathways. *Mol Psychiatry* (e-pub ahead of print 22 September 2015; doi:10.1038/mp.2015.138).

7 Otowa T, Yoshida E, Sugaya N, Yasuda S, Nishimura Y, Inoue K *et al*. Genome-wide association study of panic disorder in the Japanese population. *J Hum Genet* 2009; **54**: 122–126.

8 Otowa T, Kawamura Y, Nishida N, Sugaya N, Koike A, Yoshida E *et al*. Meta-analysis of genome-wide association studies for panic disorder in the Japanese population. *Transl Psychiatry* 2012; **2**: e186.

9 Holoshitz J. The quest for better understanding of HLA-disease association: scenes from a road less travelled by. *Discov Med* 2013; **16**: 93–101.

10 Corvin A, Morris DW. Genome-wide association studies: findings at the major histocompatibility complex locus in psychosis. *Biol Psychiatry* 2014; **75**: 276–283.

11 Shimada-Sugimoto M, Otowa T, Miyagawa T, Khor SS, Kashiwase K, Sugaya N *et al*. Immune-related pathways including HLA-DRB1(*)13:02 are associated with panic disorder. *Brain Behav Immun* 2015; **46**: 96–103.

12 Sasai T, Inoue Y, Komada Y, Sugiura T, Matsushima E. Comparison of clinical characteristics among narcolepsy with and without cataplexy and idiopathic hypersomnia without long sleep time, focusing on HLA-DRB1(*)1501/DQB1(*) 0602 finding. *Sleep Med* 2009; **10**: 961–966.

13 Sasai-Sakuma T, Inoue Y. Differences in electroencephalographic findings among categories of narcolepsy-spectrum disorders. *Sleep Med* 2015; **16**: 999–1005.

14 Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E *et al*. Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. *Nat Genet* 2013; **45**: 202–207.

15 Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet* 2009; **5**: e1000529.

16 Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D *et al*. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**: 559–575.

17 Haaker J, Lonsdorf TB, Raczka KA, Mechias ML, Gartmann N, Kalisch R. Higher anxiety and larger amygdala volumes in carriers of a TMEM132D risk variant for panic disorder. *Transl Psychiatry* 2014; **4**: e357.

18 The International HapMap Consortium. A haplotype map of the human genome. *Nature* 2005; **437**: 1299–1320.

19 The International HapMap Consortium. The International HapMap Project. *Nature* 2003; **426**: 789–796.

Supplementary Information for this article can be found on the Human Genome Variation website (http://www.nature.com/hgv)